These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6282189)

  • 1. Angiotensin converting enzyme (ACE) inhibitors.
    Antonaccio MJ
    Annu Rev Pharmacol Toxicol; 1982; 22():57-87. PubMed ID: 6282189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and pharmacology of angiotensin converting enzyme inhibitors.
    Antonaccio MJ
    J Pharmacol; 1983; 14 Suppl 3():29-45. PubMed ID: 6323887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibitors in hypertension: a review.
    Salvetti A; Pedrinelli R; Arzilli F; Abdel-Haq B; Magagna A; Lucarini A; Graziadei L; Nuccorini A; Taddei S
    Int J Clin Pharmacol Res; 1985; 5(6):429-38. PubMed ID: 3005182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of captopril and enalapril on sodium excretion and blood pressure in sodium-deficient dogs.
    McCaa RE; Gillespie JB
    Fed Proc; 1984 Apr; 43(5):1336-41. PubMed ID: 6323226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy.
    Abrams WB; Davies RO; Ferguson RK
    Fed Proc; 1984 Apr; 43(5):1314-21. PubMed ID: 6323221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Do kinins have significance for the antihypertensive effect of angiotensin-converting enzyme inhibitors?].
    Bönner G
    Z Kardiol; 1988; 77 Suppl 3():23-7. PubMed ID: 3062958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of inhibition of converting enzyme by captopril on arterial pressure, renin and aldosterone in essential hypertension].
    Posadas C; Sánchez G; Boyer JL; Delmar M; Serrano PA
    Arch Inst Cardiol Mex; 1982; 52(4):295-300. PubMed ID: 6291470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of angiotensin-converting enzyme inhibitors in congestive heart failure.
    Galvao M
    Heart Lung; 1990 Sep; 19(5 Pt 1):505-11. PubMed ID: 2211159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical pharmacology of ACE inhibitors].
    Hitzenberger G
    Wien Med Wochenschr; 1990 Jan; 140(1-2):12-8. PubMed ID: 2408245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
    Bralet J; Marie C; Mossiat C; Lecomte JM; Gros C; Schwartz JC
    J Pharmacol Exp Ther; 1994 Jul; 270(1):8-14. PubMed ID: 8035346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity.
    Zusman RM
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):13-23. PubMed ID: 3037886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
    Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ
    J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels.
    Komine N; Khang S; Wead LM; Blantz RC; Gabbai FB
    Am J Kidney Dis; 2002 Jan; 39(1):159-64. PubMed ID: 11774115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of captopril in animal models of hypertension.
    Antonaccio MJ; Rubin B; Horovitz ZP
    Clin Exp Hypertens (1978); 1980; 2(3-4):613-37. PubMed ID: 7000464
    [No Abstract]   [Full Text] [Related]  

  • 15. Evolution of angiotensin-converting enzyme inhibitors.
    Wyvratt MJ
    Clin Physiol Biochem; 1988; 6(3-4):217-29. PubMed ID: 2849521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular interactions of vasoactive systems in cardiovascular damage.
    Bader M
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S7-9. PubMed ID: 11811382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prostaglandins, kallikrein-kinin and dopamine. Practical implications of this vasodilator-natriuretic system].
    Abenhaim L; Kuchel O
    Union Med Can; 1979 Jun; 108(6):621-39. PubMed ID: 388782
    [No Abstract]   [Full Text] [Related]  

  • 18. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Captopril in primary hypertension. Effects related to the renin-angiotensin-aldosterone and kallikrein-kinin systems.
    Ohman KP; Karlberg BE; Nilsson OR; Wettre S
    Acta Med Scand Suppl; 1981; 646():98-105. PubMed ID: 7018190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common genetic variations of the renin-angiotensin-aldosterone system and response to acute angiotensin I-converting enzyme inhibition in essential hypertension.
    Hannila-Handelberg T; Kontula KK; Paukku K; Lehtonen JY; Virtamo J; Tikkanen I; Hiltunen TP
    J Hypertens; 2010 Apr; 28(4):771-9. PubMed ID: 20027122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.